Release
📈 Stocks
Hansa Biopharma Reports 90% Graft Survival Rate in Idefirix Study
(just now)
Hansa Biopharma's Idefirix achieves 90% graft failure-free survival at 12 months, with patient survival rates hitting 98%, signaling strong clinical validation for…